Abstract
Hypercalcemia in malignant lymphoma is not common. Our case of malignant lymphoma with multiple bony lesions showed hypercalcemia (13 mg/dl) at the time of bone marrow relapse. The serum level of parathyroid hormone-related peptide increased to 142 pmol/l, which may be secreted by malignant lymphoma cells. The course of the patient was aggressive and she died from bone marrow relapse after 6 months of treatment including high-dose methotrexate, which caused acute nonoliguric renal failure. At autopsy there was extensive calcium deposition in the lungs, kidneys and pancreas and prominent tubular damage of kidneys.
Copyright 2002 S. Karger AG, Basel
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Neoplasms / blood
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / pathology*
-
Child
-
Female
-
Humans
-
Hypercalcemia
-
Kidney / pathology*
-
Methotrexate / therapeutic use
-
Parathyroid Hormone-Related Protein
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
-
Proteins / metabolism*
Substances
-
Antimetabolites, Antineoplastic
-
PTHLH protein, human
-
Parathyroid Hormone-Related Protein
-
Proteins
-
Methotrexate